The transition from rapid-acting to slow-acting insulin within the Mittayi scheme has induced acute physiological volatility for children with Type 1 diabetes. Families report that current medication fails to sync with metabolic requirements, resulting in prolonged hyperglycemia, episodes of diabetic ketoacidosis (DKA), and disrupted schooling. The Type 1 Diabetes Foundation (Kerala) has formally petitioned the Chief Minister, citing that the state-supplied insulin is incompatible with the physiological speed required to stabilize blood glucose levels during standard meal windows.
Operational Friction and Health Outcomes
The shift in supply, observed since mid-2025, forces children to contend with medication that takes up to eight hours to achieve the glycemic control previously managed by rapid-acting formulas in approximately three hours.
| Insulin Type | Operational Speed | Observed Patient Consequence |
|---|---|---|
| Rapid-Acting | ~3 Hours | Precise glycemic management |
| Slow-Acting | ~8 Hours | Uncontrolled spikes; loss of consciousness |
Clinical Inconsistency: Reports indicate that children are missing meal windows entirely because the medication's lag prevents glucose regulation during the short lunch break.
Systemic Deficit: Since March 2025, supply volumes have been capped, with older children receiving limited cartridges, forcing families to source medication through private channels or face clinical degradation.
Excluded Populations: Eligibility criteria tethered to a family income limit of ₹2 lakh continue to bar over 1,200 children from the safety net, despite the increasing prevalence of the condition.
Bureaucratic Displacement
The Mittayi project, originally designed by the Kerala Social Security Mission as a holistic intervention for early diagnosis and supply-side support, is currently experiencing a rupture between state-stated mandates and ground-level clinical reality.
Read More: Officials Praise Doctors for Saving Mothers in Difficult Births in India
Parents, including representatives from the Type 1 Diabetic Welfare Society, argue that the standardization of insulin supply—ignoring individual biological variance—turns a life-saving initiative into a secondary health risk. The state's inability to maintain the quality and delivery of specialized insulin serves as a signal of institutional friction, where the bureaucratic mechanism of the Mittayi scheme prioritizes fiscal or logistical convenience over the immediate, hour-by-hour metabolic demands of its young beneficiaries.